¡Ya estamos en ! Descubre más

Regenxbio

RGNX

Capitalización de mercado USD 457 M

6.92 USD

-0.24

3.35%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

Antes de la apertura del mercado

Después del cierre del mercado

6.95

+0.03

0.43%

1 día

-3.35%

5 días

-14.78%

1 mes

-13.28%

3 meses

-38.21%

6 meses

-24.7%

En lo que va del año

-49.01%

1 año

-43.92%

5 años

-80.44%

10 años

-56.48%

Acerca de: Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.

Empleados: 371

Atención médica Biotecnología

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 17.4%

Neutral 60.9%

Negativo 21.7%

REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20

Event to include clinical program overview and perspectives from leading retina specialists ahead of topline pivotal data readout anticipated in 4Q 2026 ROCKVILLE, Md., Oct. 12, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will host an investor event at 1:00 p.m.

REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

Majority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no additional treatment for diabetic retinopathy No IOI observed with short-course prophylactic topical steroids ROCKVILLE, Md., Sept. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive long-term follow-up data from the Phase II ALTITUDE® study of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery.

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., Sept. 8, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: Baird 2026 Global Healthcare Conference Fireside Chat: Tuesday, September 15 at 8:30 a.m.

REGENXBIO to Participate in Upcoming Investor Conferences

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)

SAN DIEGO--(BUSINESS WIRE)---- $RGNX #BiotechInvesting--Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of REGENXBIO Inc. (NASDAQ: RGNX) against certain of its officers and directors for alleged breaches of fiduciary duty. Shareholders who have held REGENXBIO shares continuously since prior to February 9, 2022, may have standing to seek corporate governance reforms, the return of funds to the Company, and a court-approved incentive award, all at no cost to them. What Sho.

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)

Zacks Investment Research

RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy

REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.

RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy

Regenxbio: Sell-Off On Hunter Setback Presents A Risky Buy Opportunity

Regenxbio is rated a 'risky buy' due to high volatility, regulatory setbacks, and significant near-term catalysts. RGNX faces a clinical hold on RGX-121 for Hunter Syndrome, complicating milestone payments and royalty streams, but maintains sufficient cash runway into Q4 2027. Pivotal data for the AbbVie-partnered eye disease program and BLA submission for RGX-202 in DMD represent major binary catalysts by year-end and 2027.

Regenxbio: Sell-Off On Hunter Setback Presents A Risky Buy Opportunity

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026.

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold

SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating REGENXBIO Inc. (NASDAQ: RGNX) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws. If you purchased REGENXBIO securities and suffered losses, click here to join the investigation.

RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold

Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial

Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial for RGX-121, the company's investigational therapy for Hunter syndome.

Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™